EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events

Lehel Peterfi, Maria V Yusenko iD, Gyula Kovacs, Tamas Beothe iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25137359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Lehel Peterfi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical School, University of Pecs, 7602 Pecs, Hungary. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Kidney Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is acknowledged that conventional renal cell carcinoma (cRCC), which makes up 85% of renal malignancies, is a highly vascular tumor. Humanized monoclonal antibodies were developed to inhibit tumor neo-angiogenesis, which is driven by VEGFA/KDR signaling. The results largely met our expectations, and in several cases, adverse events occurred. Our study aimed to analyze the expression of VEGFA and its receptor KDR by immunohistochemistry in tissue multi-array containing 811 cRCC and find a correlation between VEGFA/KDR signaling and new vessel formation. None of the 811 cRCC displayed VEGFA-positive immunostaining. However, each glomerulus in normal kidney showed VEGFA-positive endothelial cells. KDR expression in endothelial meshwork was found in only 9% of cRCC, whereas 2% of the cRCC displayed positive KDR reaction in the cytoplasm of tumor cells. Our results disclose the involvement of VEGFA/KDR signaling in the neo-vascularization of cRCC and explain the frequent resistance to drugs targeting the VEGFA/KDR signaling and the high frequency of adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Kidney NeoplasmsSignal TransductionHumansFemaleMaleMiddle AgedNeovascularization, PathologicAgedMolecular Targeted TherapyAdult

Stichwörter der Autor:innen

KDRVEGFAadverse eventsimmunohistochemistryrenal cell carcinoma

Substanzen

Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanKDR protein, human

Autor:innen und Institutionen

  • Department of Urology, Medical School, University of Pecs, 7602 Pecs, Hungary.
  • Institute of Human Genetics, Ruhr-University, 44801 Bochum, Germany.
  • Medical Faculty, Ruprecht-Karls-University, 69117 Heidelberg, Germany.
  • Department of Urology, Peterfy Sandor Hospital, 1076 Budapest, Hungary.

ORCID-Profile: Maria V Yusenko, Tamas Beothe

Zitieren

APA

Peterfi, L., Yusenko, M. V., Kovacs, G., & Beothe, T. (2024). Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137359

Vancouver

Peterfi L, Yusenko MV, Kovacs G, Beothe T. Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137359

BibTeX
@article{Peterfi2024,
  author = {Peterfi, Lehel and Yusenko, Maria V and Kovacs, Gyula and Beothe, Tamas},
  title = {Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25137359}
}
Kostenlos starten →